Uncorrected Author Proof
Journal of Alzheimer’s Disease xx (20xx) x–xx
DOI 10.3233/JAD-190414
IOS Press
1
Can Subjective Memory Complaints
Identify A Positive and A Negative
Amnestic Mild Cognitive Impairment
Patients?
1
2
3
4
Tiago Mendes
a,b,∗
, Sandra Cardoso
a
, Manuela Guerreiro
a
, Jo˜ ao Maroco
c
, Dina Silva
a,d
, Lu
´
isa Alves
e
,
Ben Schmand
f
, Bianca Gerardo
h
, Marisa Lima
h
, Isabel Santana
g,h,i
and Alexandre de Mendonc ¸a
a
5
6
a
Faculty of Medicine, University of Lisboa, Lisbon, Portugal 7
b
Department of Psychiatry and Mental Health, Santa Maria Hospital, Lisbon, Portugal 8
c
Instituto Superior de Psicologia Aplicada, Lisbon, Portugal 9
d
Department of Psychology and Educational Sciences and Centre for Biomedical Research (CBMR), Cognitive
Neuroscience Research Group, Universidade do Algarve, Faro, Portugal
10
11
e
Chronic Diseases Research Centre, NOVA Medical School, NOVA University of Lisbon, Portugal 12
f
Faculty of Social and Behavioral Sciences, University of Amsterdam, the Netherlands 13
g
Department of Neurology, Centro Hospitalar e Universit´ ario de Coimbra, Portugal 14
h
Neuropsychology Unit, Centro Hospitalar e Universit´ ario de Coimbra, Portugal 15
i
Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal
16
Accepted 3 June 2019
Abstract. 17
Background: The use of biomarkers, in particular amyloid- (A) changes, has allowed the possibility to identify patients
with subjective memory complaints (SMCs) and amnestic mild cognitive impairment (aMCI) who suffer from Alzheimer’s
disease (AD). Since it is unfeasible that all patients with aMCI could presently undergo biomarkers assessment, it would be
important that SMCs might contribute to identify the aMCI patients who have AD amyloid pathology.
18
19
20
21
Objectives: To know whether aMCI patients with amyloid biomarkers (A
+
) present greater SMCs as compared to those
without amyloid biomarkers (A
−
).
22
23
Methods: Participants were selected from a cohort of nondemented patients with cognitive complaints and a comprehensive
neuropsychological evaluation, on the basis of 1) diagnosis of aMCI; 2) detailed assessment of memory difficulties with the
SMC Scale; and 3) known amyloid status. The amyloid status was determined on the basis of either CSF A
1–42
concentration
or amyloid PET imaging.
24
25
26
27
Results: Of the 176 patients with aMCI studied, 90 were A
+
and 86 were A
−
. The two groups did not differ in terms
of age, gender, and education. The SMC total score was not significantly different in the A
+
aMCI patients (9.48 ± 4.18)
when compared to the A
−
aMCI patients (10.52 ± 4.57). The A
+
aMCI patients had lower scores on the MMSE and
memory/learning tests, but not on the Geriatric Depression Scale, when comparing to the A
−
aMCI patients.
28
29
30
31
Conclusions: Evaluating SMCs does not seem helpful to identify, among patients with aMCI, those who have AD. 32
Keywords: Alzheimer’s disease, amnestic, amyloid-, anosognosia, depressive symptoms, mild cognitive impairment, sub-
jective memory complaints
33
34
∗
Correspondence to: Tiago Mendes, Dementia Clinics, Insti-
tute of Molecular Medicine and Faculty of Medicine, University of
Lisbon, Av Prof Egas Moniz, 1649-028 Lisboa, Portugal. E-mail:
tiagohmendes@outlook.pt.
ISSN 1387-2877/19/$35.00 © 2019 – IOS Press and the authors. All rights reserved